axitinib sustained release bioerodible implant (AR-14034 SR)
/ Alcon
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
February 16, 2024
NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
(clinicaltrials.gov)
- P1/2 | N=140 | Recruiting | Sponsor: Aerie Pharmaceuticals | Trial completion date: Oct 2025 ➔ Feb 2027 | Trial primary completion date: Oct 2025 ➔ Feb 2027
Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
December 15, 2023
NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
(clinicaltrials.gov)
- P1/2 | N=140 | Recruiting | Sponsor: Aerie Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
September 18, 2023
NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
(clinicaltrials.gov)
- P1/2 | N=140 | Not yet recruiting | Sponsor: Aerie Pharmaceuticals | Trial completion date: Oct 2026 ➔ Jan 2027 | Trial primary completion date: Oct 2026 ➔ Jan 2027
Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
July 20, 2023
NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
(clinicaltrials.gov)
- P1/2 | N=140 | Not yet recruiting | Sponsor: Aerie Pharmaceuticals | Initiation date: Aug 2023 ➔ Nov 2023
Trial initiation date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
April 06, 2023
AR-14034 SR Implant Inhibits Retinal Vascular Leakage In A VEGF Challenge Model For Up To 12 Months
(ARVO 2023)
- "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."
Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
March 15, 2023
NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
(clinicaltrials.gov)
- P1/2 | N=140 | Not yet recruiting | Sponsor: Aerie Pharmaceuticals
New P1/2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
1 to 6
Of
6
Go to page
1